杭州舶临医药科技

Bolin Pharma is a biotechnology company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule drugs through targeted protein degradation (TPD). The company leverages its proprietary platform to design molecular glues and PROTACs aimed at previously undruggable targets in oncology and immunology. Founded in 2021 by industry veterans with extensive experience in medicinal chemistry and drug discovery, Bolin Pharma focuses on creating next-generation therapies that overcome resistance to traditional inhibitors. The company has secured significant venture capital funding from prominent investors such as Qiming Venture Partners and GL Ventures to advance its internal pipeline. Bolin Pharma's research is primarily directed toward addressing high unmet medical needs in cancer and autoimmune disorders.